Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontak in CTCL
NCT00050999Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 1995
- Primary completion
- Sep 2006
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 4, randomised, double-blind trial of denileukin diftitox in cutaneous T-cell lymphoma (CTCL) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Objective Rate of Response. Started Jun 1995; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00050999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050999.